Venetoclax and decitabine for untreated AML in older or frail adults
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML), but not a specific subtype called acute promyelocytic leukemia (APL).
- You are either 65 years or older and choose not to have strong chemo, or you are over 18 but too weak for standard chemo due to heart, lung, kidney, or other health problems.
- You have not had any previous AML treatment (except for hydroxyurea or very low doses of cytarabine).
- Your AML is not caused by prior cancer treatment, and you have not had myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) before.
- Your heart, liver, and kidneys are working well enough (based on tests done within a week before starting the study).
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during treatment and for 3 years after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of venetoclax and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) who cannot have or choose not to have intensive chemotherapy. The goal is to see if adding a drug called cobicistat helps the treatment work better.
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.